Calliditas Therapeutics AB (publ)

As of June 30, 2024, Calliditas Therapeutics AB (publ) has 54.01M shares outstanding.

These figures are as of June 30, 2024.

These figures are as of June 30, 2024. The EV/Sales ratio of 7.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2024, Calliditas Therapeutics AB (publ) maintains a current ratio of 2.69, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 944.17, indicating elevated leverage, while an interest coverage ratio of -8.95 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -27.80, reflecting losses generated across the asset base. Inventory turnover of 3.62 indicates how many times Calliditas Therapeutics AB (publ) sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 10, 2024, Calliditas Therapeutics AB (publ)'s stock has gained approximately 101.94% over the past 52 weeks. The 50-day moving average sits at 206.68, while the 200-day moving average is 158.28.

Over the twelve months ended June 30, 2024, Calliditas Therapeutics AB (publ) posted a gross margin of 93.46, reflecting its pricing power and cost economics. The operating margin of -24.32 and net profit margin of -30.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield is negative at -2.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.78, meaning Calliditas Therapeutics AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2024, Calliditas Therapeutics AB (publ) has an Altman Z-Score of 4.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.